1
|
Mamguem Kamga A, Di Martino C, Anota A, Paget-Bailly S, Coutant C, Arveux P, Desmoulins I, Dabakuyo-Yonli TS. Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial. Trials 2020; 21:527. [PMID: 32546198 PMCID: PMC7296931 DOI: 10.1186/s13063-020-04397-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 05/08/2020] [Indexed: 01/02/2023] Open
Abstract
Background Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Thus, we hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with presentation of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC. Methods In this study, we will include 342 women with non-metastatic hormone receptor–positive BC with an indication for treatment with ET. Patients will be randomly assigned 1:1 by minimization and stratified by age, stage, type of ET prescribed, and presence of comorbidities (or not) in two arms. The intervention will consist of numerical HRQoL assessment using the CHES (Computer-based Health Evaluation System) software before each consultation (with delivery of scores to clinicians) coupled with therapeutic information. Therapeutic information will consist of three workshops related to understanding the prescription, nutrition, and fatigue. A reminder letter will be sent to patients every month. Patients in the control group will follow standard care. HRQoL will be assessed using a classic “paper-pencil” collection at baseline in both arms to ensure comparability between arms and at 12 months. The primary endpoint is 12-month compliance with ET. Patient satisfaction with care and the clinicians’ perception of the usefulness of routine HRQoL assessment will also be assessed. Discussion This study will allow clinicians to identify and better understand the areas in which patients who receive ET have difficulties and thus it will assist clinicians with patient management. Systematic evaluation of HRQoL could provide an additional endpoint for measuring patients’ health status and treatment-related symptoms, including ET. If the results of this study are positive, this intervention could be proposed as an integral part of daily clinical practice in patients who receive ET. Trial registration ClinicalTrials.govNCT04176809. Registered Nov. 25, 2019.
Collapse
Affiliation(s)
- Ariane Mamguem Kamga
- Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon Cedex, 21000, France
| | - Cyril Di Martino
- Georges François Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon, 21000, France
| | - Amelie Anota
- Methodological and Quality of Life Unit in Oncology, University Hospital Of Besançon, 3 Boulevard Alexandre Fleming, Besançon, 25000, France.,INSERM, EFS BFC, UMR1098, Interaction Hôte-Greffon-Tumeur/Ingénierie Cellulaire ET Génique, University Bourgogne Franche-Comté, 32 Avenue de l'Observatoire, Besançon, 25000, France.,National Quality of Life and Cancer Platform, 1 rue du Professeur Marion, Dijon, 21000, France
| | - Sophie Paget-Bailly
- Methodological and Quality of Life Unit in Oncology, University Hospital Of Besançon, 3 Boulevard Alexandre Fleming, Besançon, 25000, France.,INSERM, EFS BFC, UMR1098, Interaction Hôte-Greffon-Tumeur/Ingénierie Cellulaire ET Génique, University Bourgogne Franche-Comté, 32 Avenue de l'Observatoire, Besançon, 25000, France
| | - Charles Coutant
- Surgery Department, Georges François Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon, 21000, France.,Burgundy Franche-Comté University, 7 Boulevard Jeanne d'Arc, Dijon, 21000, France
| | - Patrick Arveux
- Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon Cedex, 21000, France.,Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, University Paris-Sud, UVSQ Gustave Roussy, 12 Avenue Paul Vaillant Couturier, Villejuif, 94800, France
| | - Isabelle Desmoulins
- Medical Oncology Unit, Centre Georges-François Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon, 21000, France
| | - Tienhan Sandrine Dabakuyo-Yonli
- Epidemiology and Quality of Life Research Unit, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue du Professeur Marion, Dijon Cedex, 21000, France. .,National Quality of Life and Cancer Platform, 1 rue du Professeur Marion, Dijon, 21000, France.
| |
Collapse
|